Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

(2022) Yueh-Ming Loo et al.   Science Translational Medicine

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

(2022) Robert Stuver et al.   CANCER CELL

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

(2022) Annika Fendler et al.   Nature Reviews Clinical Oncology

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

(2022) Myron J. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

(2022) Gili Regev-Yochay et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

(2022) Beomki Lee et al.   Frontiers in Cellular and Infection Microbiology

Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave

(2022) Ayman Al Jurdi et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

(2022) Aekkachai Tuekprakhon et al.   CELL

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

(2022) Qian Wang et al.   NATURE

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

(2022) Panke Qu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of SARS-CoV-2 Omicron variants on serum neutralization in a cohort of healthcare workers vaccinated with BNT162b2

(2022) Anna Gidari et al.   JOURNAL OF INFECTION

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

(2022) Daniele Focosi et al.   Viruses-Basel

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

(2022) Manish C. Choudhary et al.   Nature Microbiology

Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario

(2022) Carolin Krekeler et al.   Cancers

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

(2021) Wilfredo F. Garcia-Beltran et al.   CELL

Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

(2021) Alessandra Mazzola et al.   CLINICAL INFECTIOUS DISEASES

Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected

(2021) Anna Gidari et al.   JOURNAL OF INFECTION

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients

(2021) Cong Zeng et al.   Cell and Bioscience

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

(2020) Bina Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

(2020) Teresa Aydillo et al.   NEW ENGLAND JOURNAL OF MEDICINE